SCHEDULE 13G/A: Orca Capital AG Discloses 4.9% Stake in Pasithea Therapeutics Corp.

Orca Capital AG has filed an amended Schedule 13G, reporting a beneficial ownership of 4.9% of Pasithea Therapeutics Corp.'s common stock.

Summary

• Orca Capital AG reported beneficial ownership of 362,857 shares of Pasithea Therapeutics Corp. common stock.
• This stake represents 4.9% of the Issuer's outstanding common stock.
• The ownership percentage is calculated based on an aggregate of 6,529,291 shares of Common Stock outstanding immediately after the completion of Pasithea Therapeutics Corp.'s registered offering.
• Orca Capital AG also holds warrants for 379,427 shares of Common Stock, which are subject to a 4.99% beneficial ownership blocker, preventing exercise if it would result in ownership exceeding this threshold.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating an update to a previously filed statement.

Sentiment

Score: 6

Explanation: The filing indicates a significant, albeit passive, investment by an institutional entity, which can be viewed positively as a vote of confidence. However, it's a routine disclosure and doesn't provide new operational or financial performance data.

Positives

• The disclosure of a significant stake by Orca Capital AG, an institutional investor, can be interpreted as a vote of confidence in Pasithea Therapeutics Corp.
• The 4.99% blocker on warrants suggests a passive investment intent, which may indicate stability and a lack of immediate intent to influence control, potentially reassuring other investors.

Risks

• The 4.99% beneficial ownership blocker on warrants limits Orca Capital AG's ability to increase its stake above this threshold without triggering more stringent reporting requirements (e.g., Schedule 13D), which could cap their potential future investment or influence.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on beneficial ownership disclosure.

Industry Context

This Schedule 13G filing indicates a significant passive investment by Orca Capital AG in Pasithea Therapeutics Corp. Such filings are common in the investment landscape, reflecting institutional interest in publicly traded companies. The 4.9% stake, just below the 5% threshold for more active reporting (Schedule 13D), suggests a strategic decision by the investor to maintain a passive position, which is a common practice for funds that do not intend to influence control or management.

Comparison to Industry Standards

• This filing is a standard disclosure of beneficial ownership and does not contain financial results or operational metrics that can be directly compared to industry benchmarks or specific comparable companies/projects.
• The 4.9% stake is a notable position for an institutional investor, indicating a significant, albeit passive, interest in the company.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially offering reassurance or insight into institutional interest.
• Company Management: Awareness of a large, passive investor holding just under the 5% threshold.

Next Steps

• The document does not specify any future actions, events, or milestones for Pasithea Therapeutics Corp. or Orca Capital AG beyond the filing itself.

Key Dates

Keywords

Pasithea Therapeutics Corp., Orca Capital AG, Schedule 13G, beneficial ownership, common stock, equity stake, SEC filing, investment, warrants, institutional investor